Research programme: ZEB antagonists - Centre for Drug Design and Discovery
Latest Information Update: 04 Oct 2022
At a glance
- Originator Centre for Drug Design and Discovery
- Class Antineoplastics
- Mechanism of Action Homeodomain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 28 Sep 2022 Research programme: ZEB antagonists - Centre for Drug Design and Discovery is available for licensing as of 21 Sep 2022. https://www.cd3.be/collaboration
- 21 Sep 2022 Early research in Solid tumours in Belgium (unspecified route) (Centre for Drug Design and Discovery website, September 2022)